메뉴 건너뛰기




Volumn 6, Issue 12, 2011, Pages

Prediction of effect of pegylated interferon alpha-2b plus ribavirin combination therapy in patients with chronic hepatitis C infection

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN; RIBAVIRIN;

EID: 82555168483     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027223     Document Type: Article
Times cited : (10)

References (42)
  • 1
    • 1842479859 scopus 로고    scopus 로고
    • Diagnosis, management, and treatment of hepatitis C
    • Strader DB, Wright T, Thomas DL, Seeff LB, (2004) Diagnosis, management, and treatment of hepatitis C. Hepatology 39: 1147-1171.
    • (2004) Hepatology , vol.39 , pp. 1147-1171
    • Strader, D.B.1    Wright, T.2    Thomas, D.L.3    Seeff, L.B.4
  • 2
    • 0030587906 scopus 로고    scopus 로고
    • Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group
    • Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, et al. (1996) Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med 125: 634-639.
    • (1996) Ann Intern Med , vol.125 , pp. 634-639
    • Zein, N.N.1    Rakela, J.2    Krawitt, E.L.3    Reddy, K.R.4    Tominaga, T.5
  • 3
    • 10344259671 scopus 로고    scopus 로고
    • Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study
    • Dusheiko G, Main J, Thomas H, Reichard O, Lee C, et al. (1996) Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 25: 591-598.
    • (1996) J Hepatol , vol.25 , pp. 591-598
    • Dusheiko, G.1    Main, J.2    Thomas, H.3    Reichard, O.4    Lee, C.5
  • 4
    • 0028202422 scopus 로고
    • Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey
    • McOmish F, Yap PL, Dow BC, Follett EA, Seed C, et al. (1994) Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 32: 884-892.
    • (1994) J Clin Microbiol , vol.32 , pp. 884-892
    • McOmish, F.1    Yap, P.L.2    Dow, B.C.3    Follett, E.A.4    Seed, C.5
  • 5
    • 0028812140 scopus 로고
    • Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group
    • Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, et al. (1995) Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann Intern Med 122: 161-168.
    • (1995) Ann Intern Med , vol.122 , pp. 161-168
    • Nousbaum, J.B.1    Pol, S.2    Nalpas, B.3    Landais, P.4    Berthelot, P.5
  • 6
    • 0027193157 scopus 로고
    • Differences in the hepatitis C virus genotypes in different countries
    • Takada N, Takase S, Takada A, Date T, (1993) Differences in the hepatitis C virus genotypes in different countries. J Hepatol 17: 277-283.
    • (1993) J Hepatol , vol.17 , pp. 277-283
    • Takada, N.1    Takase, S.2    Takada, A.3    Date, T.4
  • 7
    • 33645992473 scopus 로고    scopus 로고
    • Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin
    • Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, et al. (2006) Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130: 1086-1097.
    • (2006) Gastroenterology , vol.130 , pp. 1086-1097
    • Berg, T.1    von Wagner, M.2    Nasser, S.3    Sarrazin, C.4    Heintges, T.5
  • 8
    • 1542378867 scopus 로고    scopus 로고
    • Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose
    • Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, et al. (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346-355.
    • (2004) Ann Intern Med , vol.140 , pp. 346-355
    • Hadziyannis, S.J.1    Sette Jr., H.2    Morgan, T.R.3    Balan, V.4    Diago, M.5
  • 9
    • 1442308277 scopus 로고    scopus 로고
    • Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?
    • Zeuzem S, (2004) Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 140: 370-381.
    • (2004) Ann Intern Med , vol.140 , pp. 370-381
    • Zeuzem, S.1
  • 10
    • 2442683905 scopus 로고    scopus 로고
    • Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3
    • Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, et al. (2004) Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 40: 993-999.
    • (2004) J Hepatol , vol.40 , pp. 993-999
    • Zeuzem, S.1    Hultcrantz, R.2    Bourliere, M.3    Goeser, T.4    Marcellin, P.5
  • 11
    • 36348981708 scopus 로고    scopus 로고
    • Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial
    • Jacobson IM, Brown RS Jr, Freilich B, Afdhal N, Kwo PY, et al. (2007) Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 46: 971-981.
    • (2007) Hepatology , vol.46 , pp. 971-981
    • Jacobson, I.M.1    Brown Jr., R.S.2    Freilich, B.3    Afdhal, N.4    Kwo, P.Y.5
  • 12
    • 33746564989 scopus 로고    scopus 로고
    • Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment
    • Sanchez-Tapias JM, Diago M, Escartin P, Enriquez J, Romero-Gomez M, et al. (2006) Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 131: 451-460.
    • (2006) Gastroenterology , vol.131 , pp. 451-460
    • Sanchez-Tapias, J.M.1    Diago, M.2    Escartin, P.3    Enriquez, J.4    Romero-Gomez, M.5
  • 13
    • 40549128699 scopus 로고    scopus 로고
    • Possible molecular mechanism of the relationship between NS5B polymorphisms and early clearance of hepatitis C virus during interferon plus ribavirin treatment
    • Nakamura M, Saito H, Ikeda M, Tada S, Kumagai N, et al. (2008) Possible molecular mechanism of the relationship between NS5B polymorphisms and early clearance of hepatitis C virus during interferon plus ribavirin treatment. J Med Virol 80: 632-639.
    • (2008) J Med Virol , vol.80 , pp. 632-639
    • Nakamura, M.1    Saito, H.2    Ikeda, M.3    Tada, S.4    Kumagai, N.5
  • 14
    • 0034010610 scopus 로고    scopus 로고
    • Immunological and virological predictors of outcome during interferon-alpha therapy of chronic hepatitis C
    • Saito H, Ebinuma H, Satoh I, Miyaguchi S, Tada S, et al. (2000) Immunological and virological predictors of outcome during interferon-alpha therapy of chronic hepatitis C. J Viral Hepat 7: 64-74.
    • (2000) J Viral Hepat , vol.7 , pp. 64-74
    • Saito, H.1    Ebinuma, H.2    Satoh, I.3    Miyaguchi, S.4    Tada, S.5
  • 15
    • 0036376634 scopus 로고    scopus 로고
    • The detection of IRF-1 promoter polymorphisms and their possible contribution to T helper 1 response in chronic hepatitis C
    • Saito H, Tada S, Wakabayashi K, Nakamoto N, Takahashi M, et al. (2002) The detection of IRF-1 promoter polymorphisms and their possible contribution to T helper 1 response in chronic hepatitis C. J Interferon Cytokine Res 22: 693-700.
    • (2002) J Interferon Cytokine Res , vol.22 , pp. 693-700
    • Saito, H.1    Tada, S.2    Wakabayashi, K.3    Nakamoto, N.4    Takahashi, M.5
  • 16
    • 36248957151 scopus 로고    scopus 로고
    • Introduction to artificial neural networks
    • Grossi E, Buscema M, (2007) Introduction to artificial neural networks. Eur J Gastroenterol Hepatol 19: 1046-1054.
    • (2007) Eur J Gastroenterol Hepatol , vol.19 , pp. 1046-1054
    • Grossi, E.1    Buscema, M.2
  • 18
    • 0028788276 scopus 로고
    • Application of artificial neural networks to clinical medicine
    • Baxt WG, (1995) Application of artificial neural networks to clinical medicine. Lancet 346: 1135-1138.
    • (1995) Lancet , vol.346 , pp. 1135-1138
    • Baxt, W.G.1
  • 20
    • 33846683604 scopus 로고    scopus 로고
    • International experience on the use of artificial neural networks in gastroenterology
    • Grossi E, Mancini A, Buscema M, (2007) International experience on the use of artificial neural networks in gastroenterology. Dig Liver Dis 39: 278-285.
    • (2007) Dig Liver Dis , vol.39 , pp. 278-285
    • Grossi, E.1    Mancini, A.2    Buscema, M.3
  • 21
    • 36248953324 scopus 로고    scopus 로고
    • The use of artificial neural network in gastroenterology: the experience of the first 10 years
    • Pace F, Savarino V, (2007) The use of artificial neural network in gastroenterology: the experience of the first 10 years. Eur J Gastroenterol Hepatol 19: 1043-1045.
    • (2007) Eur J Gastroenterol Hepatol , vol.19 , pp. 1043-1045
    • Pace, F.1    Savarino, V.2
  • 22
    • 0031781450 scopus 로고    scopus 로고
    • The impact of chronic hepatitis C virus infection on HIV disease and progression in intravenous drug users
    • Haydon GH, Flegg PJ, Blair CS, Brettle RP, Burns SM, et al. (1998) The impact of chronic hepatitis C virus infection on HIV disease and progression in intravenous drug users. Eur J Gastroenterol Hepatol 10: 485-489.
    • (1998) Eur J Gastroenterol Hepatol , vol.10 , pp. 485-489
    • Haydon, G.H.1    Flegg, P.J.2    Blair, C.S.3    Brettle, R.P.4    Burns, S.M.5
  • 23
    • 3042684526 scopus 로고    scopus 로고
    • Artificial neural networks for the prediction of response to interferon plus ribavirin treatment in patients with chronic hepatitis C
    • Maiellaro PA, Cozzolongo R, Marino P, (2004) Artificial neural networks for the prediction of response to interferon plus ribavirin treatment in patients with chronic hepatitis C. Curr Pharm Des 10: 2101-2109.
    • (2004) Curr Pharm Des , vol.10 , pp. 2101-2109
    • Maiellaro, P.A.1    Cozzolongo, R.2    Marino, P.3
  • 24
    • 36248986257 scopus 로고    scopus 로고
    • Prediction of outcome in acute lower gastrointestinal hemorrhage: role of artificial neural network
    • Das A, Wong RC, (2007) Prediction of outcome in acute lower gastrointestinal hemorrhage: role of artificial neural network. Eur J Gastroenterol Hepatol 19: 1064-1069.
    • (2007) Eur J Gastroenterol Hepatol , vol.19 , pp. 1064-1069
    • Das, A.1    Wong, R.C.2
  • 25
    • 0142155223 scopus 로고    scopus 로고
    • Prediction of outcome in acute lower-gastrointestinal haemorrhage based on an artificial neural network: internal and external validation of a predictive model
    • Das A, Ben-Menachem T, Cooper GS, Chak A, Sivak MV Jr, et al. (2003) Prediction of outcome in acute lower-gastrointestinal haemorrhage based on an artificial neural network: internal and external validation of a predictive model. Lancet 362: 1261-1266.
    • (2003) Lancet , vol.362 , pp. 1261-1266
    • Das, A.1    Ben-Menachem, T.2    Cooper, G.S.3    Chak, A.4    Sivak Jr., M.V.5
  • 26
    • 0031871764 scopus 로고    scopus 로고
    • Prediction of cirrhosis in patients with chronic hepatitis C infection by artificial neural network analysis of virus and clinical factors
    • Haydon GH, Jalan R, Ala-Korpela M, Hiltunen Y, Hanley J, et al. (1998) Prediction of cirrhosis in patients with chronic hepatitis C infection by artificial neural network analysis of virus and clinical factors. J Viral Hepat 5: 255-264.
    • (1998) J Viral Hepat , vol.5 , pp. 255-264
    • Haydon, G.H.1    Jalan, R.2    Ala-Korpela, M.3    Hiltunen, Y.4    Hanley, J.5
  • 27
    • 0036792679 scopus 로고    scopus 로고
    • Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection
    • Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, et al. (2002) Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 97: 2614-2618.
    • (2002) Am J Gastroenterol , vol.97 , pp. 2614-2618
    • Regev, A.1    Berho, M.2    Jeffers, L.J.3    Milikowski, C.4    Molina, E.G.5
  • 28
    • 34748866821 scopus 로고    scopus 로고
    • Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b
    • Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, et al. (2007) Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol 79: 1686-1695.
    • (2007) J Med Virol , vol.79 , pp. 1686-1695
    • Akuta, N.1    Suzuki, F.2    Kawamura, Y.3    Yatsuji, H.4    Sezaki, H.5
  • 29
    • 34547428001 scopus 로고    scopus 로고
    • Predictors of response of US veterans to treatment for the hepatitis C virus
    • Backus LI, Boothroyd DB, Phillips BR, Mole LA, (2007) Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 46: 37-47.
    • (2007) Hepatology , vol.46 , pp. 37-47
    • Backus, L.I.1    Boothroyd, D.B.2    Phillips, B.R.3    Mole, L.A.4
  • 30
    • 0034632938 scopus 로고    scopus 로고
    • Formula optimization of theophylline controlled-release tablet based on artificial neural networks
    • Takayama K, Morva A, Fujikawa M, Hattori Y, Obata Y, et al. (2000) Formula optimization of theophylline controlled-release tablet based on artificial neural networks. J Control Release 68: 175-186.
    • (2000) J Control Release , vol.68 , pp. 175-186
    • Takayama, K.1    Morva, A.2    Fujikawa, M.3    Hattori, Y.4    Obata, Y.5
  • 31
    • 0041733248 scopus 로고    scopus 로고
    • Clinical application of artificial neural network (ANN) modelling to predict pharmacokinetic parameters of severely ill patients
    • Yamamura S, (2003) Clinical application of artificial neural network (ANN) modelling to predict pharmacokinetic parameters of severely ill patients. Adv Drug Deliv Rev 55: 1233-1251.
    • (2003) Adv Drug Deliv Rev , vol.55 , pp. 1233-1251
    • Yamamura, S.1
  • 32
    • 0025934806 scopus 로고
    • Use of an artificial neural network for the diagnosis of myocardial infarction
    • Baxt WG, (1991) Use of an artificial neural network for the diagnosis of myocardial infarction. Ann Intern Med 115: 843-848.
    • (1991) Ann Intern Med , vol.115 , pp. 843-848
    • Baxt, W.G.1
  • 33
    • 58149380829 scopus 로고    scopus 로고
    • Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors
    • Shirakawa H, Matsumoto A, Joshita S, Komatsu M, Tanaka N, et al. (2008) Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 48: 1753-1760.
    • (2008) Hepatology , vol.48 , pp. 1753-1760
    • Shirakawa, H.1    Matsumoto, A.2    Joshita, S.3    Komatsu, M.4    Tanaka, N.5
  • 34
    • 31644439149 scopus 로고    scopus 로고
    • Insertion and deletion analyses identify regions of non-structural protein 5A of Hepatitis C virus that are dispensable for viral genome replication
    • Liu S, Ansari IH, Das SC, Pattnaik AK, (2006) Insertion and deletion analyses identify regions of non-structural protein 5A of Hepatitis C virus that are dispensable for viral genome replication. J Gen Virol 87: 323-327.
    • (2006) J Gen Virol , vol.87 , pp. 323-327
    • Liu, S.1    Ansari, I.H.2    Das, S.C.3    Pattnaik, A.K.4
  • 35
    • 70349292099 scopus 로고    scopus 로고
    • Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
    • Ge D, Fellay J, Thompson A, Simon J, Shianna K, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nat Genet 461: 399-401.
    • (2009) Nat Genet , vol.461 , pp. 399-401
    • Ge, D.1    Fellay, J.2    Thompson, A.3    Simon, J.4    Shianna, K.5
  • 36
    • 70349533037 scopus 로고    scopus 로고
    • Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
    • Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105-1109.
    • (2009) Nat Genet , vol.41 , pp. 1105-1109
    • Tanaka, Y.1    Nishida, N.2    Sugiyama, M.3    Kurosaki, M.4    Matsuura, K.5
  • 37
    • 70349548852 scopus 로고    scopus 로고
    • IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy
    • Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41: 1100-1104.
    • (2009) Nat Genet , vol.41 , pp. 1100-1104
    • Suppiah, V.1    Moldovan, M.2    Ahlenstiel, G.3    Berg, T.4    Weltman, M.5
  • 38
    • 79953298817 scopus 로고    scopus 로고
    • IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection
    • Lin CY, Chen JY, Lin TN, Jeng WJ, Huang CH, et al. (2011) IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS ONE 6: e21854.
    • (2011) PLoS ONE , vol.6
    • Lin, C.Y.1    Chen, J.Y.2    Lin, T.N.3    Jeng, W.J.4    Huang, C.H.5
  • 39
    • 79960081869 scopus 로고    scopus 로고
    • An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C
    • O'Brien TR, Everhart JE, Morgan TR, Lok AS, Chung RT, et al. (2011) An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLoS ONE 6: e20904.
    • (2011) PLoS ONE , vol.6
    • O'Brien, T.R.1    Everhart, J.E.2    Morgan, T.R.3    Lok, A.S.4    Chung, R.T.5
  • 40
    • 79960022080 scopus 로고    scopus 로고
    • Characterization of serum proteins associated with IL28B genotype among patients with chronic hepatitis C
    • Cyr DD, Lucas JE, Thompson JW, Patel K, Clark PJ, et al. (2011) Characterization of serum proteins associated with IL28B genotype among patients with chronic hepatitis C. PLoS ONE 6: e21854.
    • (2011) PLoS ONE , vol.6
    • Cyr, D.D.1    Lucas, J.E.2    Thompson, J.W.3    Patel, K.4    Clark, P.J.5
  • 41
    • 77952693487 scopus 로고    scopus 로고
    • Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin
    • McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, et al. (2010) Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 138: 2307-2314.
    • (2010) Gastroenterology , vol.138 , pp. 2307-2314
    • McCarthy, J.J.1    Li, J.H.2    Thompson, A.3    Suchindran, S.4    Lao, X.Q.5
  • 42
    • 77956882389 scopus 로고    scopus 로고
    • Creation of a tablet database containing several active ingredients and prediction of their pharmaceutical characteristics based on ensemble artificial neural networks
    • Takagaki K, Arai H, Takayama K, (2010) Creation of a tablet database containing several active ingredients and prediction of their pharmaceutical characteristics based on ensemble artificial neural networks. J Pharm Sci 99: 4201-4214.
    • (2010) J Pharm Sci , vol.99 , pp. 4201-4214
    • Takagaki, K.1    Arai, H.2    Takayama, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.